| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $61,809 | 3 | 100 |
Sells | $0 | 0 | 0 |
| Teleman Dan Benjamin | Chief Executive Officer | 3 | $61,809 | 0 | $0 | $61,809 |
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel …
Over the last 12 months, insiders at Nasus Pharma Ltd. have bought $61,809 and sold $0 worth of Nasus Pharma Ltd. stock.
On average, over the past 5 years, insiders at Nasus Pharma Ltd. have bought $61,809 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Teleman Dan Benjamin (Chief Executive Officer) — $61,809.
The last purchase of 6,550 shares for transaction amount of $20,305 was made by Teleman Dan Benjamin (Chief Executive Officer) on 2026‑06‑17.
| 2026-06-17 | Teleman Dan Benjamin | Chief Executive Officer | 6,550 0.0765% | $3.10 | $20,305 | +10.23% | ||
| 2026-04-22 | Teleman Dan Benjamin | Chief Executive Officer | 2,900 0.0396% | $3.76 | $10,904 | -16.71% | ||
| 2026-03-31 | Teleman Dan Benjamin | Chief Executive Officer | 15,000 0.16% | $2.04 | $30,600 | +44.14% |
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | <1 | -33.33% | 863 | -26.63% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 2 | -33.33% | 2,378 | -26.63% |